nodes	percent_of_prediction	percent_of_DWPC	metapath
Naratriptan—Polydipsia—Furosemide—dilated cardiomyopathy	0.0268	0.0369	CcSEcCtD
Naratriptan—Diuresis—Furosemide—dilated cardiomyopathy	0.0268	0.0369	CcSEcCtD
Naratriptan—Atrial flutter—Lisinopril—dilated cardiomyopathy	0.0164	0.0226	CcSEcCtD
Naratriptan—Pyelonephritis—Lisinopril—dilated cardiomyopathy	0.0164	0.0226	CcSEcCtD
Naratriptan—Ulcer—Spironolactone—dilated cardiomyopathy	0.0161	0.0222	CcSEcCtD
Naratriptan—Transient ischaemic attack—Lisinopril—dilated cardiomyopathy	0.0123	0.017	CcSEcCtD
Naratriptan—Glycosuria—Furosemide—dilated cardiomyopathy	0.0103	0.0141	CcSEcCtD
Naratriptan—Cramp muscle—Spironolactone—dilated cardiomyopathy	0.00998	0.0138	CcSEcCtD
Naratriptan—Gastritis—Spironolactone—dilated cardiomyopathy	0.00981	0.0135	CcSEcCtD
Naratriptan—Hyperlipidaemia—Lisinopril—dilated cardiomyopathy	0.00865	0.0119	CcSEcCtD
Naratriptan—Drowsiness—Spironolactone—dilated cardiomyopathy	0.00854	0.0118	CcSEcCtD
Naratriptan—Ventricular fibrillation—Lisinopril—dilated cardiomyopathy	0.00814	0.0112	CcSEcCtD
Naratriptan—Urine output increased—Furosemide—dilated cardiomyopathy	0.00751	0.0104	CcSEcCtD
Naratriptan—Bladder pain—Furosemide—dilated cardiomyopathy	0.00751	0.0104	CcSEcCtD
Naratriptan—Ventricular extrasystoles—Lisinopril—dilated cardiomyopathy	0.0069	0.00951	CcSEcCtD
Naratriptan—Photosensitivity—Furosemide—dilated cardiomyopathy	0.00687	0.00947	CcSEcCtD
Naratriptan—Polyuria—Furosemide—dilated cardiomyopathy	0.00687	0.00947	CcSEcCtD
Naratriptan—Swelling—Furosemide—dilated cardiomyopathy	0.00683	0.00942	CcSEcCtD
Naratriptan—Alopecia—Spironolactone—dilated cardiomyopathy	0.00678	0.00934	CcSEcCtD
Naratriptan—Vascular purpura—Furosemide—dilated cardiomyopathy	0.00674	0.00929	CcSEcCtD
Naratriptan—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.00642	0.00884	CcSEcCtD
Naratriptan—Thirst—Furosemide—dilated cardiomyopathy	0.00634	0.00873	CcSEcCtD
Naratriptan—Purpura—Furosemide—dilated cardiomyopathy	0.00626	0.00862	CcSEcCtD
Naratriptan—Ventricular tachycardia—Lisinopril—dilated cardiomyopathy	0.00623	0.00859	CcSEcCtD
Naratriptan—Anaphylactoid reaction—Furosemide—dilated cardiomyopathy	0.00623	0.00859	CcSEcCtD
Naratriptan—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00619	0.00854	CcSEcCtD
Naratriptan—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.00609	0.00839	CcSEcCtD
Naratriptan—Malaise—Spironolactone—dilated cardiomyopathy	0.00602	0.0083	CcSEcCtD
Naratriptan—Cystitis—Lisinopril—dilated cardiomyopathy	0.00602	0.0083	CcSEcCtD
Naratriptan—Fluid retention—Lisinopril—dilated cardiomyopathy	0.00592	0.00816	CcSEcCtD
Naratriptan—Photophobia—Lisinopril—dilated cardiomyopathy	0.00585	0.00807	CcSEcCtD
Naratriptan—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00563	0.00777	CcSEcCtD
Naratriptan—Discomfort—Spironolactone—dilated cardiomyopathy	0.00561	0.00774	CcSEcCtD
Naratriptan—Dehydration—Furosemide—dilated cardiomyopathy	0.00561	0.00773	CcSEcCtD
Naratriptan—Confusional state—Spironolactone—dilated cardiomyopathy	0.00549	0.00757	CcSEcCtD
Naratriptan—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00545	0.00751	CcSEcCtD
Naratriptan—Cramp muscle—Furosemide—dilated cardiomyopathy	0.00543	0.00748	CcSEcCtD
Naratriptan—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00533	0.00735	CcSEcCtD
Naratriptan—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.00523	0.0072	CcSEcCtD
Naratriptan—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.00515	0.0071	CcSEcCtD
Naratriptan—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.0051	0.00704	CcSEcCtD
Naratriptan—Libido decreased—Lisinopril—dilated cardiomyopathy	0.00488	0.00672	CcSEcCtD
Naratriptan—HTR1B—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.00487	0.0178	CbGpPWpGaD
Naratriptan—Somnolence—Spironolactone—dilated cardiomyopathy	0.00484	0.00667	CcSEcCtD
Naratriptan—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00481	0.00664	CcSEcCtD
Naratriptan—HTR1D—Monoamine GPCRs—ADRB2—dilated cardiomyopathy	0.0048	0.0175	CbGpPWpGaD
Naratriptan—Atrial fibrillation—Lisinopril—dilated cardiomyopathy	0.00477	0.00658	CcSEcCtD
Naratriptan—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.00476	0.00656	CcSEcCtD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00473	0.0172	CbGpPWpGaD
Naratriptan—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.0047	0.00648	CcSEcCtD
Naratriptan—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.0047	0.00648	CcSEcCtD
Naratriptan—HTR1B—Monoamine GPCRs—ADRB2—dilated cardiomyopathy	0.0047	0.0171	CbGpPWpGaD
Naratriptan—Anaphylactoid reaction—Lisinopril—dilated cardiomyopathy	0.00467	0.00644	CcSEcCtD
Naratriptan—Drowsiness—Furosemide—dilated cardiomyopathy	0.00465	0.0064	CcSEcCtD
Naratriptan—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00462	0.00636	CcSEcCtD
Naratriptan—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00449	0.00619	CcSEcCtD
Naratriptan—Disturbance in sexual arousal—Lisinopril—dilated cardiomyopathy	0.00449	0.00619	CcSEcCtD
Naratriptan—Sweating—Furosemide—dilated cardiomyopathy	0.00445	0.00614	CcSEcCtD
Naratriptan—MAOA—SIDS Susceptibility Pathways—SCN5A—dilated cardiomyopathy	0.00445	0.0162	CbGpPWpGaD
Naratriptan—HTR1A—Monoamine GPCRs—ADRB1—dilated cardiomyopathy	0.00442	0.0161	CbGpPWpGaD
Naratriptan—Urticaria—Spironolactone—dilated cardiomyopathy	0.00433	0.00596	CcSEcCtD
Naratriptan—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00431	0.00594	CcSEcCtD
Naratriptan—HTR1F—GPCRs, Other—CXCR3—dilated cardiomyopathy	0.00425	0.0155	CbGpPWpGaD
Naratriptan—Dehydration—Lisinopril—dilated cardiomyopathy	0.00421	0.0058	CcSEcCtD
Naratriptan—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.00407	0.00562	CcSEcCtD
Naratriptan—HTR1D—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.00403	0.0147	CbGpPWpGaD
Naratriptan—MAOA—Oxidative Stress—SOD2—dilated cardiomyopathy	0.00403	0.0147	CbGpPWpGaD
Naratriptan—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00401	0.00553	CcSEcCtD
Naratriptan—Gastritis—Lisinopril—dilated cardiomyopathy	0.004	0.00552	CcSEcCtD
Naratriptan—HTR1B—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.00395	0.0144	CbGpPWpGaD
Naratriptan—Asthma—Lisinopril—dilated cardiomyopathy	0.00391	0.00539	CcSEcCtD
Naratriptan—Tinnitus—Furosemide—dilated cardiomyopathy	0.00389	0.00536	CcSEcCtD
Naratriptan—Pruritus—Spironolactone—dilated cardiomyopathy	0.00385	0.00531	CcSEcCtD
Naratriptan—MAOA—Oxidative Stress—GPX1—dilated cardiomyopathy	0.00384	0.014	CbGpPWpGaD
Naratriptan—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00381	0.00525	CcSEcCtD
Naratriptan—Angiopathy—Furosemide—dilated cardiomyopathy	0.00378	0.00522	CcSEcCtD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—SCN5A—dilated cardiomyopathy	0.00378	0.0138	CbGpPWpGaD
Naratriptan—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00377	0.00519	CcSEcCtD
Naratriptan—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00376	0.00518	CcSEcCtD
Naratriptan—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00373	0.00514	CcSEcCtD
Naratriptan—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00373	0.00514	CcSEcCtD
Naratriptan—HTR1A—Amine ligand-binding receptors—ADRB1—dilated cardiomyopathy	0.00371	0.0135	CbGpPWpGaD
Naratriptan—Erythema—Furosemide—dilated cardiomyopathy	0.00363	0.00501	CcSEcCtD
Naratriptan—Dizziness—Spironolactone—dilated cardiomyopathy	0.0036	0.00497	CcSEcCtD
Naratriptan—HTR1A—Monoamine GPCRs—ADRB2—dilated cardiomyopathy	0.00358	0.013	CbGpPWpGaD
Naratriptan—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.00357	0.00492	CcSEcCtD
Naratriptan—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00353	0.00486	CcSEcCtD
Naratriptan—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00351	0.00483	CcSEcCtD
Naratriptan—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00349	0.00481	CcSEcCtD
Naratriptan—Depression—Lisinopril—dilated cardiomyopathy	0.00348	0.00479	CcSEcCtD
Naratriptan—Vomiting—Spironolactone—dilated cardiomyopathy	0.00346	0.00477	CcSEcCtD
Naratriptan—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00344	0.00474	CcSEcCtD
Naratriptan—Rash—Spironolactone—dilated cardiomyopathy	0.00343	0.00473	CcSEcCtD
Naratriptan—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00343	0.00473	CcSEcCtD
Naratriptan—Vision blurred—Furosemide—dilated cardiomyopathy	0.00342	0.00472	CcSEcCtD
Naratriptan—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00342	0.00471	CcSEcCtD
Naratriptan—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00342	0.00471	CcSEcCtD
Naratriptan—Headache—Spironolactone—dilated cardiomyopathy	0.00341	0.0047	CcSEcCtD
Naratriptan—Anaemia—Furosemide—dilated cardiomyopathy	0.00336	0.00463	CcSEcCtD
Naratriptan—Sweating—Lisinopril—dilated cardiomyopathy	0.00334	0.00461	CcSEcCtD
Naratriptan—Agitation—Furosemide—dilated cardiomyopathy	0.00334	0.0046	CcSEcCtD
Naratriptan—HTR1F—GPCRs, Other—ADRB2—dilated cardiomyopathy	0.00333	0.0121	CbGpPWpGaD
Naratriptan—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00327	0.00451	CcSEcCtD
Naratriptan—Vertigo—Furosemide—dilated cardiomyopathy	0.00326	0.0045	CcSEcCtD
Naratriptan—Nausea—Spironolactone—dilated cardiomyopathy	0.00324	0.00446	CcSEcCtD
Naratriptan—Bradycardia—Lisinopril—dilated cardiomyopathy	0.00319	0.00439	CcSEcCtD
Naratriptan—MAOA—SIDS Susceptibility Pathways—RYR2—dilated cardiomyopathy	0.00317	0.0116	CbGpPWpGaD
Naratriptan—Hallucination—Lisinopril—dilated cardiomyopathy	0.00311	0.00429	CcSEcCtD
Naratriptan—Dry mouth—Furosemide—dilated cardiomyopathy	0.00302	0.00417	CcSEcCtD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00302	0.011	CbGpPWpGaD
Naratriptan—HTR1A—Amine ligand-binding receptors—ADRB2—dilated cardiomyopathy	0.00301	0.011	CbGpPWpGaD
Naratriptan—Confusional state—Furosemide—dilated cardiomyopathy	0.00299	0.00412	CcSEcCtD
Naratriptan—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00296	0.00408	CcSEcCtD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00296	0.0108	CbGpPWpGaD
Naratriptan—Tinnitus—Lisinopril—dilated cardiomyopathy	0.00292	0.00402	CcSEcCtD
Naratriptan—Shock—Furosemide—dilated cardiomyopathy	0.00292	0.00402	CcSEcCtD
Naratriptan—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00291	0.00401	CcSEcCtD
Naratriptan—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.0029	0.004	CcSEcCtD
Naratriptan—Skin disorder—Furosemide—dilated cardiomyopathy	0.00288	0.00397	CcSEcCtD
Naratriptan—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00286	0.00395	CcSEcCtD
Naratriptan—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00284	0.00391	CcSEcCtD
Naratriptan—Chills—Lisinopril—dilated cardiomyopathy	0.00281	0.00387	CcSEcCtD
Naratriptan—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.0028	0.00385	CcSEcCtD
Naratriptan—Hypotension—Furosemide—dilated cardiomyopathy	0.00277	0.00382	CcSEcCtD
Naratriptan—Alopecia—Lisinopril—dilated cardiomyopathy	0.00277	0.00381	CcSEcCtD
Naratriptan—Erythema—Lisinopril—dilated cardiomyopathy	0.00272	0.00376	CcSEcCtD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—RYR2—dilated cardiomyopathy	0.0027	0.00982	CbGpPWpGaD
Naratriptan—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00266	0.00367	CcSEcCtD
Naratriptan—Somnolence—Furosemide—dilated cardiomyopathy	0.00263	0.00363	CcSEcCtD
Naratriptan—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00262	0.00361	CcSEcCtD
Naratriptan—Vision blurred—Lisinopril—dilated cardiomyopathy	0.00257	0.00354	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00256	0.00353	CcSEcCtD
Naratriptan—Fatigue—Furosemide—dilated cardiomyopathy	0.00256	0.00352	CcSEcCtD
Naratriptan—Tremor—Lisinopril—dilated cardiomyopathy	0.00255	0.00352	CcSEcCtD
Naratriptan—Constipation—Furosemide—dilated cardiomyopathy	0.00253	0.00349	CcSEcCtD
Naratriptan—Pain—Furosemide—dilated cardiomyopathy	0.00253	0.00349	CcSEcCtD
Naratriptan—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00253	0.00348	CcSEcCtD
Naratriptan—Anaemia—Lisinopril—dilated cardiomyopathy	0.00252	0.00347	CcSEcCtD
Naratriptan—Malaise—Lisinopril—dilated cardiomyopathy	0.00246	0.00339	CcSEcCtD
Naratriptan—Vertigo—Lisinopril—dilated cardiomyopathy	0.00245	0.00337	CcSEcCtD
Naratriptan—Syncope—Lisinopril—dilated cardiomyopathy	0.00244	0.00337	CcSEcCtD
Naratriptan—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00244	0.00337	CcSEcCtD
Naratriptan—Palpitations—Lisinopril—dilated cardiomyopathy	0.00241	0.00332	CcSEcCtD
Naratriptan—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00239	0.0033	CcSEcCtD
Naratriptan—Cough—Lisinopril—dilated cardiomyopathy	0.00238	0.00328	CcSEcCtD
Naratriptan—Urticaria—Furosemide—dilated cardiomyopathy	0.00235	0.00325	CcSEcCtD
Naratriptan—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00234	0.00323	CcSEcCtD
Naratriptan—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00232	0.0032	CcSEcCtD
Naratriptan—Myalgia—Lisinopril—dilated cardiomyopathy	0.00232	0.0032	CcSEcCtD
Naratriptan—Anxiety—Lisinopril—dilated cardiomyopathy	0.00231	0.00319	CcSEcCtD
Naratriptan—Discomfort—Lisinopril—dilated cardiomyopathy	0.00229	0.00316	CcSEcCtD
Naratriptan—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00227	0.00313	CcSEcCtD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—MAS1—dilated cardiomyopathy	0.00225	0.00821	CbGpPWpGaD
Naratriptan—MAOA—Transmission across Chemical Synapses—ACTN2—dilated cardiomyopathy	0.00225	0.00821	CbGpPWpGaD
Naratriptan—Confusional state—Lisinopril—dilated cardiomyopathy	0.00224	0.00309	CcSEcCtD
Naratriptan—Oedema—Lisinopril—dilated cardiomyopathy	0.00222	0.00306	CcSEcCtD
Naratriptan—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00222	0.00306	CcSEcCtD
Naratriptan—Infection—Lisinopril—dilated cardiomyopathy	0.00221	0.00304	CcSEcCtD
Naratriptan—Shock—Lisinopril—dilated cardiomyopathy	0.00219	0.00302	CcSEcCtD
Naratriptan—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00218	0.00301	CcSEcCtD
Naratriptan—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00218	0.003	CcSEcCtD
Naratriptan—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00216	0.00298	CcSEcCtD
Naratriptan—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00215	0.00296	CcSEcCtD
Naratriptan—HTR1F—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.00214	0.00779	CbGpPWpGaD
Naratriptan—HTR1F—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.00214	0.00779	CbGpPWpGaD
Naratriptan—Asthenia—Furosemide—dilated cardiomyopathy	0.00213	0.00293	CcSEcCtD
Naratriptan—Pruritus—Furosemide—dilated cardiomyopathy	0.0021	0.00289	CcSEcCtD
Naratriptan—Hypotension—Lisinopril—dilated cardiomyopathy	0.00208	0.00286	CcSEcCtD
Naratriptan—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00203	0.00279	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00203	0.00279	CcSEcCtD
Naratriptan—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.002	0.00275	CcSEcCtD
Naratriptan—HTR1F—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.00199	0.00724	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.00198	0.00723	CbGpPWpGaD
Naratriptan—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00198	0.00273	CcSEcCtD
Naratriptan—Somnolence—Lisinopril—dilated cardiomyopathy	0.00198	0.00272	CcSEcCtD
Naratriptan—Dizziness—Furosemide—dilated cardiomyopathy	0.00196	0.0027	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00192	0.00265	CcSEcCtD
Naratriptan—Fatigue—Lisinopril—dilated cardiomyopathy	0.00192	0.00264	CcSEcCtD
Naratriptan—Constipation—Lisinopril—dilated cardiomyopathy	0.0019	0.00262	CcSEcCtD
Naratriptan—Pain—Lisinopril—dilated cardiomyopathy	0.0019	0.00262	CcSEcCtD
Naratriptan—Vomiting—Furosemide—dilated cardiomyopathy	0.00188	0.0026	CcSEcCtD
Naratriptan—Rash—Furosemide—dilated cardiomyopathy	0.00187	0.00258	CcSEcCtD
Naratriptan—Dermatitis—Furosemide—dilated cardiomyopathy	0.00187	0.00257	CcSEcCtD
Naratriptan—Headache—Furosemide—dilated cardiomyopathy	0.00186	0.00256	CcSEcCtD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.00185	0.00672	CbGpPWpGaD
Naratriptan—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00183	0.00253	CcSEcCtD
Naratriptan—MAOA—Neuronal System—ABCC9—dilated cardiomyopathy	0.0018	0.00656	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.00179	0.00651	CbGpPWpGaD
Naratriptan—Urticaria—Lisinopril—dilated cardiomyopathy	0.00177	0.00243	CcSEcCtD
Naratriptan—Nausea—Furosemide—dilated cardiomyopathy	0.00176	0.00243	CcSEcCtD
Naratriptan—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00176	0.00242	CcSEcCtD
Naratriptan—MAOA—Neuronal System—ACTN2—dilated cardiomyopathy	0.00173	0.00629	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.0017	0.0062	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.0017	0.0062	CbGpPWpGaD
Naratriptan—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00164	0.00226	CcSEcCtD
Naratriptan—Asthenia—Lisinopril—dilated cardiomyopathy	0.0016	0.0022	CcSEcCtD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00158	0.00576	CbGpPWpGaD
Naratriptan—Pruritus—Lisinopril—dilated cardiomyopathy	0.00157	0.00217	CcSEcCtD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.00153	0.00558	CbGpPWpGaD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.00153	0.00556	CbGpPWpGaD
Naratriptan—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00152	0.0021	CcSEcCtD
Naratriptan—Dizziness—Lisinopril—dilated cardiomyopathy	0.00147	0.00203	CcSEcCtD
Naratriptan—HTR1F—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.00145	0.00527	CbGpPWpGaD
Naratriptan—Vomiting—Lisinopril—dilated cardiomyopathy	0.00141	0.00195	CcSEcCtD
Naratriptan—Rash—Lisinopril—dilated cardiomyopathy	0.0014	0.00193	CcSEcCtD
Naratriptan—Dermatitis—Lisinopril—dilated cardiomyopathy	0.0014	0.00193	CcSEcCtD
Naratriptan—Headache—Lisinopril—dilated cardiomyopathy	0.00139	0.00192	CcSEcCtD
Naratriptan—HTR1D—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.00137	0.00498	CbGpPWpGaD
Naratriptan—HTR1D—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.00137	0.00498	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.00134	0.00488	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.00134	0.00488	CbGpPWpGaD
Naratriptan—Nausea—Lisinopril—dilated cardiomyopathy	0.00132	0.00182	CcSEcCtD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.00131	0.00476	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.0013	0.00472	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.0013	0.00472	CbGpPWpGaD
Naratriptan—HTR1D—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.00127	0.00463	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.00127	0.00462	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.00125	0.00454	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.00124	0.00453	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.00124	0.00452	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	0.00124	0.00451	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.0012	0.00439	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.00118	0.0043	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.00117	0.00425	CbGpPWpGaD
Naratriptan—HTR1F—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.00116	0.00422	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.00116	0.00421	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.00114	0.00416	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.00112	0.00408	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.00109	0.00396	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.00109	0.00396	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.00107	0.00391	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.00106	0.00388	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.00106	0.00388	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	0.00105	0.00383	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—CXCL2—dilated cardiomyopathy	0.00102	0.00372	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—AGTR2—dilated cardiomyopathy	0.00102	0.00372	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00101	0.00368	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000996	0.00363	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.00099	0.00361	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000979	0.00357	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000976	0.00356	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000959	0.00349	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000956	0.00348	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—CXCR3—dilated cardiomyopathy	0.000949	0.00346	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—AGTR2—dilated cardiomyopathy	0.000947	0.00345	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000945	0.00344	CbGpPWpGaD
Naratriptan—HTR1D—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000926	0.00337	CbGpPWpGaD
Naratriptan—HTR1F—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.00092	0.00335	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.000912	0.00332	CbGpPWpGaD
Naratriptan—HTR1B—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000907	0.0033	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—CXCR3—dilated cardiomyopathy	0.00088	0.00321	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—ADRB1—dilated cardiomyopathy	0.000852	0.00311	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000836	0.00305	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000828	0.00302	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000828	0.00302	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000819	0.00298	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—AGTR2—dilated cardiomyopathy	0.000811	0.00296	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL2—dilated cardiomyopathy	0.000811	0.00296	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000811	0.00295	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000811	0.00295	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000793	0.00289	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000777	0.00283	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.00077	0.0028	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000754	0.00275	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000754	0.00275	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000746	0.00272	CbGpPWpGaD
Naratriptan—HTR1D—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.00074	0.0027	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000732	0.00267	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000732	0.00267	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.00073	0.00266	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.00073	0.00266	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—AGTR1—dilated cardiomyopathy	0.000728	0.00265	CbGpPWpGaD
Naratriptan—HTR1B—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000725	0.00264	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ANKRD1—dilated cardiomyopathy	0.000704	0.00256	CbGpPWpGaD
Naratriptan—HTR1F—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000701	0.00255	CbGpPWpGaD
Naratriptan—HTR1A—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000691	0.00252	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.00068	0.00248	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000665	0.00242	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000665	0.00242	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—TAZ—dilated cardiomyopathy	0.000662	0.00241	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000659	0.0024	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000637	0.00232	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—AGTR1—dilated cardiomyopathy	0.000624	0.00227	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000624	0.00227	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000618	0.00225	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000618	0.00225	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000618	0.00225	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000604	0.0022	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—SDHA—dilated cardiomyopathy	0.000599	0.00218	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000598	0.00218	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000592	0.00216	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000592	0.00215	CbGpPWpGaD
Naratriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000588	0.00214	CbGpPWpGaD
Naratriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000576	0.0021	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000574	0.00209	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000563	0.00205	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000556	0.00203	CbGpPWpGaD
Naratriptan—HTR1A—G alpha (i) signalling events—AGT—dilated cardiomyopathy	0.000552	0.00201	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000534	0.00194	CbGpPWpGaD
Naratriptan—MAOA—Transmission across Chemical Synapses—RAF1—dilated cardiomyopathy	0.000513	0.00187	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000511	0.00186	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000485	0.00177	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.000475	0.00173	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000468	0.0017	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000468	0.0017	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000458	0.00167	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000458	0.00167	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000451	0.00164	CbGpPWpGaD
Naratriptan—HTR1D—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000448	0.00163	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000442	0.00161	CbGpPWpGaD
Naratriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000439	0.0016	CbGpPWpGaD
Naratriptan—HTR1B—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000439	0.0016	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000435	0.00158	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000426	0.00155	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000425	0.00155	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000425	0.00155	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000421	0.00154	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000416	0.00152	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000416	0.00152	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000414	0.00151	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000413	0.0015	CbGpPWpGaD
Naratriptan—MAOA—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000409	0.00149	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000396	0.00144	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000395	0.00144	CbGpPWpGaD
Naratriptan—MAOA—Neuronal System—RAF1—dilated cardiomyopathy	0.000393	0.00143	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000393	0.00143	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000393	0.00143	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000387	0.00141	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000383	0.00139	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000376	0.00137	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000375	0.00136	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000365	0.00133	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.00036	0.00131	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—AGT—dilated cardiomyopathy	0.00036	0.00131	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000353	0.00129	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000352	0.00128	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000349	0.00127	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000349	0.00127	CbGpPWpGaD
Naratriptan—HTR1A—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	0.000347	0.00127	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000341	0.00124	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000334	0.00122	CbGpPWpGaD
Naratriptan—HTR1A—GPCR ligand binding—AGT—dilated cardiomyopathy	0.000334	0.00122	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000327	0.00119	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	0.000325	0.00118	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.00032	0.00117	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CXCL2—dilated cardiomyopathy	0.000317	0.00115	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—AGTR2—dilated cardiomyopathy	0.000317	0.00115	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	0.000314	0.00115	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.00031	0.00113	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000304	0.00111	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000302	0.0011	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CXCR3—dilated cardiomyopathy	0.000295	0.00107	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000286	0.00104	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—ADRB1—dilated cardiomyopathy	0.000285	0.00104	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000283	0.00103	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000277	0.00101	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	0.000268	0.000978	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000265	0.000966	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.00026	0.000945	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	0.000255	0.000928	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000253	0.000923	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000251	0.000915	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000251	0.000915	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.00025	0.000909	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000248	0.000903	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000246	0.000897	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000246	0.000896	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000246	0.000896	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—AGTR1—dilated cardiomyopathy	0.000244	0.000888	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000241	0.000877	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.000236	0.000859	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000233	0.00085	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—ADRB2—dilated cardiomyopathy	0.000231	0.000842	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—AGT—dilated cardiomyopathy	0.00023	0.000838	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000229	0.000833	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000226	0.000823	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000225	0.00082	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000222	0.00081	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000221	0.000806	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—AGT—dilated cardiomyopathy	0.000212	0.000774	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000211	0.000768	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—RAC1—dilated cardiomyopathy	0.000198	0.00072	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000193	0.000703	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000189	0.000689	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—AGT—dilated cardiomyopathy	0.000189	0.000688	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000187	0.000682	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000187	0.000682	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000183	0.000667	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—RAC1—dilated cardiomyopathy	0.00018	0.000654	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000179	0.000653	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000174	0.000634	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—AGT—dilated cardiomyopathy	0.000172	0.000625	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000171	0.000623	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000169	0.000614	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—GPX1—dilated cardiomyopathy	0.000163	0.000592	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.00016	0.000581	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CD36—dilated cardiomyopathy	0.000158	0.000577	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000157	0.000573	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000156	0.000569	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000154	0.000561	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—RAF1—dilated cardiomyopathy	0.000147	0.000537	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000144	0.000525	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—AGT—dilated cardiomyopathy	0.000143	0.000519	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000142	0.000518	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000139	0.000507	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000137	0.000498	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—AGT—dilated cardiomyopathy	0.000136	0.000495	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—AGT—dilated cardiomyopathy	0.000133	0.000485	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—RAF1—dilated cardiomyopathy	0.000119	0.000434	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000117	0.000428	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000109	0.000399	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—EGFR—dilated cardiomyopathy	0.000107	0.00039	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000106	0.000386	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—AGT—dilated cardiomyopathy	0.000101	0.000369	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—EGFR—dilated cardiomyopathy	0.000101	0.000368	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—RAF1—dilated cardiomyopathy	9.43e-05	0.000343	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—RAF1—dilated cardiomyopathy	9.23e-05	0.000336	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—EGFR—dilated cardiomyopathy	8.16e-05	0.000297	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—RAF1—dilated cardiomyopathy	7.03e-05	0.000256	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—EGFR—dilated cardiomyopathy	6.47e-05	0.000236	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—EGFR—dilated cardiomyopathy	6.33e-05	0.000231	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—EGFR—dilated cardiomyopathy	4.82e-05	0.000176	CbGpPWpGaD
